Novavax vaccine was 96% effective against parent strain of COVID-19

American society Novavax confirmed this Thursday that its Covid-19 vaccine shows 96% efficacy against the original strain of the infectious disease.

Likewise, he explained that said efficiency is 89.7% in total Yes 86.3% against the British variant (B.1.1.7) which has been shown to be more transmissible and the cause of more severe forms of the disease.

The results come from phase 3 clinical trials conducted in the UK with over 15,000 participants aged 18 to 84, 27% of whom were over 65.

With 89.3% effectiveness, the Novavax vaccine will soon join the favorites

The vaccine was particularly effective against severe forms of the disease. In South Africa, un smallest phase 2b trial with around 2,600 people showed the vaccine to be 48.6% effective.

Unlike immunizers from Pfizer, Moderna and AstraZeneca, Doses of Novavax inject synthetic versions of these proteins directly into the body.

Maryland-based company said he hoped to seek approval for his vaccine in the UK early in the second quarter of 2021, and that she intends to do so in the United States shortly thereafter.

JFG